Cardiology, radiology professionals unite to explore the challenges of diagnosing CAD in women

Coronary artery disease (CAD) is both underdiagnosed and undertreated in women, and they often receive less guideline-recommended care than men. Why do these disparities persist? And what can today’s healthcare providers do to bring about change?

A new webinar hosted by Cardiovascular Business and Heartflow, a leader in artificial intelligence-based coronary CT angiography (CCTA) evaluations, aims to address those very questions. The webinar will include in-depth talks from three clinicians who specialize in the diagnosis and management of CAD in women. A live Q&A session will follow. 

Specialists participating in the webinar include:

  • Malissa Wood, MD, vice president and chief physician executive of the Lee Health Heart Institute and a professor at Florida State College of Medicine
  • Cristina Fuss, MD, PhD, chief of cardiothoracic imaging and a professor of radiology and biomedical imaging at Yale School of Medicine
  • Daniela Crousillat, MD, director of the Tampa General Hospital Women's Heart Program and a cardiologist and echocardiographer with USF Health

Wood, Fuss and Crousillat will discuss their own perspective on this topic and explore the potential impact of pairing CCTA with advanced technologies to help identify more women with CAD.

This webinar was designed to help healthcare executives, cardiologists, interventional cardiologists, cardiac imaging specialists, radiologists, cardiovascular service line and cath lab directors, imaging leaders, CT technologists and any other healthcare professionals working to improve care for women with suspected CAD. 

The webinar, “Challenges of Diagnosing CAD in Women,” is scheduled for 12:30 p.m. ET on Tuesday, April 22. Participation is 100% free. 

Click here for information about how to register and other important details.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.